EmGenisys has secured a central IRB approval and launched a multi-site embryo data study in partnership with the University of Pennsylvania and Women’s Fertility and Specialty Center in Clovis, California. The company submitted two research abstracts for presentation at the American Association of Bioanalysts conference in Las Vegas in May — and a team member earned the conference’s Fellowship Award, which includes travel sponsorship to attend.
Cara Wells, EmGenisys CEO
“We’re trying to take everything that we’ve learned in animals — the biological principles, the signatures we see in their activity data, and the machine learning model infrastructures — and rinse and repeat those methodologies for use in human IVF,” Cara Wells, founder and CEO, told bizblip. The company has spent five years developing and refining its embryo-assessment methods in cattle. Wells said the goal is to use that trial-and-error experience to accelerate progress in human fertility.
EmGenisys analyzes short microscope-recorded embryo videos to help clinicians identify which embryos are most likely to result in a successful pregnancy. Founded in 2019, the company operates a cattle IVF division with customers globally under the product name Envision, and is also testing an embryo sex prediction tool called Engender. Its human fertility division operates as Viable Bio Sciences.
EmGenisys has raised more than $1 million in grants and competition awards and closed a $1.5 million seed round led by Grit Road Partners. The company has also applied for a €2.5 million European Innovation Council grant.
Links:
